We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency’s (EMA) human medicines committee recommended two new drugs for approval at its monthly meeting last week, including a Sanofi biologic for a rare disorder and a generic of Novartis’ oncology drug Glivac (imatinib). Read More
The FDA has granted full approval for Merck’s blockbuster cancer drug Keytruda (pembrolizumab) in combination with Merck and Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) for treating advanced endometrial carcinoma. Read More
Sanofi and nonprofit partners in Africa have won FDA approval for the first oral treatment for sleeping sickness. In addition to the approval, the FDA granted the partners a priority review voucher (PRV) worth millions of dollars. Read More
The FDA has denied Ardelyx’s new drug application (NDA) for tenapanor as a treatment for chronic kidney disease in adults on dialysis, citing concerns over the treatment’s effectiveness. Read More
The EMA’s human medicines committee is assessing data from two clinical trials and is expected to reach a decision by October, unless more information is required. Read More
Prograf, which is the first FDA-approved immunosuppressant for this treatment group, was previously cleared to prevent organ rejection in liver, kidney and heart transplant patients. Read More
The approval includes an updated indication for patients who are ineligible for chemotherapy containing cisplatin and those who have received at least one prior line of therapy. Read More
Darzalex Faspro is the only subcutaneous anti-CD38 monoclonal antibody cleared for use with the anti-cancer regimen pomalidomide and dexamethasone. Read More